CH
MCRB icon

CVI Holdings’s Seres Therapeutics MCRB Stock Holding History

CVI Holdings’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-136,141
Closed -$9.34M – 885
2022
Q2 		$9.34M Buy
+136,141
New +$11.7M 0.68% 20
2019
Q3 		– Sell
-11,290
Closed -$727K – 54
2019
Q2 		$727K Buy
+11,290
New +$1.07M 0.84% 22

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

CVI Holdings's MCRB Position: Q3 2022 in Review

CVI Holdings sold out of Seres Therapeutics (MCRB) in Q3 2022, closing a stake of 136,141 shares — an estimated $9.34M sold.

CVI Holdings first reported a position in MCRB in Q2 2019 and held it in 2 quarters. The position peaked at $9.34M in Q2 2022. 119 funds tracked by Wall St. Rank hold MCRB as of Q3 2022.

  • CVI Holdings reported no remaining Seres Therapeutics position as of Q3 2022 after selling out during the quarter.
  • CVI Holdings sold 136,141 Seres Therapeutics shares in Q3 2022, an estimated $9.34M.
  • CVI Holdings first reported a position in Seres Therapeutics in Q2 2019 and held it in 2 quarters.
  • CVI Holdings's Seres Therapeutics position peaked at $9.34M in Q2 2022.
  • 119 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2022.

Based on CVI Holdings's 13F filing for Q3 2022, filed 14 Nov 2022.